Navigation Links
ARIUS recognized for entrepreneurial excellence

Dr. David S. Young awarded "Most Innovative" award by the Association of

Chinese Canadian Entrepreneurs

TORONTO, April 7 /PRNewswire-FirstCall/ - ARIUS Research Inc. (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that Dr. David S. Young, President and Chief Executive Officer, received the "Most Innovative" award at the Chinese Canadian Entrepreneur Awards, held on April 5th, 2008 in Toronto, Ontario.

"The FunctionFIRST(TM) antibody discovery platform pioneered by our CEO is the foundation of our company and exemplifies the exceptional innovation that this award honours," said Warren Whitehead, Chief Financial Officer of ARIUS. "As we transition to a clinical company this year, we are proud that ARIUS' mission to generate and develop anti-cancer, antibody drugs has been recognized through this honour."

The Chinese Canadian Entrepreneur Awards, sponsored by the Association of Chinese Canadian Entrepreneurs (ACCE), annually recognizes high achievements by business people and entrepreneurs who have strengthened the competitiveness of Chinese Canadian business community in the global market. The Most Innovative Award is presented to an individual, team of individuals or company who have demonstrated exceptional innovation in their given field and contributed great value to the marketplace.


ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit

Forward-Looking Statements

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in ARIUS' Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities available at Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments.

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
2. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
3. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
4. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
5. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
6. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
7. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
8. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
9. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
10. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
11. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015  Symic, a clinical-stage biotherapeutics company ... matrix (ECM), today announced that it has secured $25 ... company,s pipeline, including its lead candidates SB-030 and SB-061. ... the participation by all existing major investors, as well ... total capital raised by Symic to over $43 million ...
(Date:12/1/2015)... December 1, 2015 ... the  "2016 U.K. Virology and Bacteriology Testing ... 100 Tests, Supplier Shares by Test, Innovative ... their offering.  --> ) ... U.K. Virology and Bacteriology Testing Market: Sales ...
(Date:11/30/2015)... radiology technique shows promise for helping morbidly obese patients lose ... presented today at the annual meeting of the Radiological Society ... --> --> Gastric artery embolization ... way to stop bleeding in emergency situations, but the idea ... is new. Mubin Syed , M.D., interventional radiologist ...
(Date:11/30/2015)... CALGARY , Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics ... appointed Dr. Norman C.W. Wong to its Board ... Wong comes to Zenith with a wealth of experience as ... and molecular biology. --> --> ... joining Zenith Epigenetics, board of directors. Zenith,s long standing expertise ...
Breaking Biology Technology:
(Date:11/19/2015)...  Although some 350 companies are actively involved in ... companies, according to Kalorama Information. These include Roche Diagnostics, Hologic, ... share of the 6.1 billion-dollar molecular testing market, according ... Molecular Diagnostic s .    ... by one company and only a handful of companies ...
(Date:11/17/2015)... -- Paris from 17 th ... Paris from 17 th until 19 th ... has invented the first combined scanner in the world which ... surface. Until now two different scanners were required: one for ... on the same surface. This innovation is an ideal ...
(Date:11/17/2015)... Nov. 17, 2015 Pressure BioSciences, Inc. (OTCQB: ... development and sale of broadly enabling, pressure cycling technology ... industry, today announced it has received gross proceeds of ... Private Placement (the "Offering"), increasing the total amount raised ... more additional closings are expected in the near future. ...
Breaking Biology News(10 mins):